Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

Fig. 2

EGFR and HER2 expression and phosphorylation in therapy sensitive and resistant variants. SKBR3 therapy sensitive or resistant (Gef.R 0.1 μM, Gef. R 0.5 μM and Lap. R 0.1 μM) cells treated with gefitinib or lapatinib for 24 h were lysed and western blotted for total and active (phospho) EGFR and HER2. a Representative western blots for pEGFR/EGFR (left) and pHER2/HER2 (right), with actin as a loading control, for cells treated with gefitinib or lapatinib for 24 h. b Fold change in EGFR and HER2 expression and phosphorylation for the therapy sensitive SKBR3 cells from positive bands quantified using image J software. c Representative western blots for pEGFR/EGFR and pHER2/HER2 in therapy sensitive (SKBR3) or resistant (Gef R, LapR variants, maintained in the indicated concentrations of gefitinib or lapatinib. d Fold change in EGFR expression, e Fold change in HER2 expression, f Fold change in EGFR phosphorylation, g Fold change in HER2 phosphorylation, N = 3 ± SEM. **** = p ≤ 0.001, *** = p ≤ 0.005, ** = p ≤ 0.01, * = p ≤ 0.05

Back to article page